New hope for rare leukemia: aggressive combo therapy shows promise
NCT ID NCT02858999
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tested a powerful combination of chemotherapy drugs followed by stem cell transplants in 40 patients under 70 with primary plasma cell leukemia, a rare and aggressive blood cancer. The goal was to see if this intensive approach could improve how long patients live without the disease coming back. The study also collected blood and bone marrow samples to better understand the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
combination chemotherapy (bortezomib, dexamethasone, doxorubicin, cyclophosphamide) followed by stem cell transplant
What this could lead to
If successful, this approach could improve disease-free survival and offer a more effective treatment strategy for this rare and aggressive blood cancer.
What could go wrong
This is a small, early-phase trial with only 40 participants, so results may not apply to all patients. The intensive treatment carries significant risks, including side effects from chemotherapy and transplant complications.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HP
Paris, 75004, France
-
CH Dunkerque
Dunkirk, 59385, France
-
CH Pays d'Aix
Aix-en-Provence, 13616, France
-
CHRU Lille
Lille, 59037, France
-
CHU Amiens
Amiens, 80054, France
-
CHU Besançon
Besançon, 25030, France
-
CHU Caen
Caen, 14033, France
-
CHU Clermont Ferrand
Clermont-Ferrand, 63003, France
-
CHU Dijon
Dijon, 21034, France
-
CHU Nancy
Nancy, 54035, France
-
CHU Nantes
Nantes, 44093, France
-
CHU Nice
Nice, 06003, France
-
CHU Poitiers
Poitiers, 86021, France
-
CHU Rennes
Rennes, 35033, France
-
CHU Strasbourg
Strasbourg, 67091, France
-
CHU Toulouse
Toulouse, 31059, France
-
CHU Tours
Tours, 37044, France
-
Hospices Civils de Lyon
Lyon, 69229, France